John C. Morris MDHarvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology; Professor of Pathology and Immunology; Professor of Physical Therapy; Professor of Occupational Therapy; Director, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri
John C. Morris, MD, is the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology; Professor of Pathology and Immunology; Professor of Physical Therapy; Professor of Occupational Therapy; and Director of the Charles F. and Joanne Knight Alzheimer's Disease Research Center at Washington University School of Medicine. Dr. Morris’ research interests include healthy aging and Alzheimer dementia, antecedent biomarkers for Alzheimer disease, and trials of investigational drugs for the treatment of Alzheimer dementia. Dr. Morris has authored 4 books and more than 700 published articles (current h-index 145). Dr. Morris is a member of several professional societies and serves on numerous scientific and community advisory boards. He has received many honors and awards, including the MetLife Award for Medical Research in Alzheimer’s Disease (2004); the Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Dementias (2005); and the Carl and Gerty Cori Faculty Achievement Award, Washington University (2010). In 2013, he received the 2013 Peter H. Raven Lifetime Achievement Award from the Academy of Science of St. Louis, the Washington University School of Medicine Second Century Award, and the 2013 Medical & Scientific Honoree from the Alzheimer’s Association He is ranked in the top 1% of investigators in the field of Neuroscience and Behavior by Essential Science Indicators database.
Dr. Morris is funded by NIH grants # P30 AG066444; P01AG003991; P01AG026276; U19 AG032438; and U19 AG024904. He serves on the Editorial Boards of Brain & Life and Alzheimer’s & Dementia. Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company.